Despite the growing body of clinical trials assessing A2AR inhibitors across various other cancers, such as renal cell cancer and non-small cell lung cancer,24,25 a gap in preclinical evidence has notably limited the examination of their efficacy in OSCC contexts. Here, ADORA2A is linked to non-small cell lung carcinoma.